


Listing of the Claims:

The current status of all claims is listed below and supersedes all previous lists of claims.

Please amend claims 1, 4, 6-7, and 16-17. Please cancel claims 5, 8, and 12-15, and add new claims 18-28.

1. (currently amended) A compound in accord with structural diagram I:

**I**

wherein:

R^1 at each occurrence is independently selected from CN, CF_3 , OCF_3 , $OCHF_2$, halogen, C_{2-4} alkenyl, C_{2-4} alkynyl, $[[R^a, R^b,]]$ hydrogen, C_{1-6} alkyl, $C(O)R^c$, $C(O)NHR^c$, CO_2R^c , $[[SR^a,]]$ NR^aR^b , $CH_2NR^aR^b$, OR^a $[[or]]$ and CH_2OR^a , where wherein R^a and R^b are independently at each occurrence hydrogen, C_{1-6} alkyl, $C(O)R^c$, $C(O)NHR^c$ or CO_2R^c $[[,]]$; and where wherein where R^c at each occurrence is C_{1-6} alkyl; or, R^a and R^b together are $(CH_2)_jG(CH_2)_k$ or $G(CH_2)_jG$, where G is oxygen or sulfur, j is 1, 2, 3 or 4, and k is 0, 1 or 2;

m is 1, 2 or 3 where at least one R^1 moiety is other than hydrogen;

R^2 and R^3 are independently hydrogen, C_{1-6} alkyl or C_{1-6} alkyl substituted with C_{1-4} alkoxy;

R^4 at each occurrence is independently selected from hydrogen, $[[CN,]]$ CF_3 , OCF_3 , $OCHF_2$, halogen, C_{1-4} alkyl, C_{2-4} alkenyl, C_{2-4} alkynyl, SR^a , NR^aR^b , $CH_2NR^aR^b$, OR^a $[[or]]$ and CH_2OR^a , where wherein R^a and R^b are independently at each occurrence hydrogen, C_{1-6} alkyl, $C(O)R^c$, $C(O)NHR^c$ or CO_2R^c $[[,]]$; where and wherein R^c at each occurrence is C_{1-6} alkyl; or, R^a and R^b together are $(CH_2)_jG(CH_2)_k$ or $G(CH_2)_jG$; and

n is 0, 1, 2 or 3;

G is oxygen or sulfur;

j is 1, 2, 3 or 4;

k is [[0,]] 1 or 2;

or a pharmaceutically-acceptable salt thereof.

2. (previously presented) A compound according to Claim 1, wherein:

R^1 independently at each occurrence is CN, C_{1-6} alkyl or OR^c ; and m is 1, 2 or 3;

R^2 and R^3 are independently hydrogen or C_{1-6} alkyl, and

R^4 independently at each occurrence is halogen where n is 1 or 2;

or a pharmaceutically-acceptable salt thereof.

3. (previously presented) A compound according to Claim 1, wherein:

R^1 independently at each occurrence is CN, ethyl or methoxy and m is 1, 2 or 3;


R^2 and R^3 are independently hydrogen or methyl, and

R^4 independently at each occurrence is halogen where n is 1 or 2;

R^4 independently at each occurrence is halogen where n is 1 or 2;

or a pharmaceutically-acceptable salt thereof.

4. (currently amended) A compound according to Claim 1, according to structural diagram II



II

wherein Ar is selected from phenyl, 3,4-dichlorophenyl, 3-fluorophenyl, 4-fluorophenyl, 3,4-difluorophenyl, 4-methoxyphenyl, 3,4-dimethoxyphenyl, 3,4-methylenedioxyphenyl, 4-difluoromethoxyphenyl [[or]] and 4-trifluoromethoxyphenyl;

R^1 is selected from H, methyl, ethyl ~~[[or]]~~ and methoxy where m is 1 or 2, and R^2 and R^3 are independently is selected from H ~~[[or]]~~ and methyl, and or a pharmaceutically-acceptable salt thereof.

5. (canceled)

6. (currently amended) ~~[[A]]~~ The pharmaceutically-acceptable salt ~~of a compound according to Claim 1~~Claim 5, wherein said salt is formed from an inorganic or organic acid ~~inorganic and organic acid~~ is selected from hydrochloric, hydrobromic, sulfuric, phosphoric, methanesulfonic, sulfamic, para-toluenesulfonic, acetic, citric, lactic, tartaric, malonic, fumaric, ethanesulfonic, benzenesulfonic, cyclohexylsulfamic, salicyclic and quinic acids.

7. (currently amended) A pharmaceutical composition comprising a compound ~~according~~ according to Claim 1, or a pharmaceutically-acceptable salt thereof, and a pharmaceutically-acceptable carrier.

8.-9. (canceled)

10. (currently amended) A method for treating a disorder or condition selected from ~~hypertension, depression in cancer patients, depression in Parkinson's patients, postmyocardial infarction depression, subsyndromal symptomatic depression, depression in infertile women, pediatric depression, major depression, single episode depression, recurrent depression, child abuse induced depression, and post partum depression, generalized anxiety disorder, agoraphobia, social phobia, simple phobias, posttraumatic stress syndrome, avoidant personality disorder, premature ejaculation, anorexia nervosa, bulimia nervosa, obesity, addictions to alcohol, cocaine, heroin, phenobarbital, nicotine or benzodiazepines, cluster headache, migraine, pain, Alzheimer's disease, obsessive compulsive disorder, panic disorder, dementia, amnesic disorders, age-related cognitive decline, dementia in Parkinson's disease, neuroleptic-induced parkinsonism, tardive dyskinesias, hyperprolactinaemia, vasospasm, cerebral vasculature vasospasm, cerebellar ataxia, gastrointestinal tract disorders, negative symptoms of schizophrenia, premenstrual syndrome, fibromyalgia syndrome, stress incontinence, Tourette's~~

~~syndrome, trichotillomania, kleptomania, male impotence, attention deficit hyperactivity disorder, chronic paroxysmal hemierania and headache associated with vascular disorders in a mammal, comprising administering an effective amount of a compound according to Claim 1, or a pharmaceutically-acceptable salt thereof, effective in treating such disorder or condition and a pharmaceutically-acceptable carrier.~~

11.-15. (canceled).

16. (currently amended) A method for treating ~~a disorder or condition selected from, depression in cancer patients, depression in Parkinson's patients, postmyocardial infarction depression, subsyndromal symptomatic depression, depression in infertile women, pediatric depression, major depression, single episode depression, recurrent depression, child abuse induced depression, post partum depression,~~ comprising administering an effective amount of a compound according to Claim 1, or a pharmaceutically-acceptable salt thereof, ~~effective in treating such disorder or condition~~ and a pharmaceutically-acceptable carrier.

17. (currently amended) A method for treating ~~a disorder or condition selected from generalized anxiety disorder, agoraphobia, social phobia, simple phobias, posttraumatic stress syndrome, avoidant personality disorder, obsessive compulsive disorder, panic disorder,~~ comprising administering an effective amount of a compound according to Claim 1, or a pharmaceutically-acceptable salt thereof, ~~effective in treating such disorder or condition~~ and a pharmaceutically-acceptable carrier.

18. (new) A method for treating a disorder or condition selected from depression in cancer patients, depression in Parkinson's patients, postmyocardial infarction depression, subsyndromal symptomatic depression, depression in infertile women, pediatric depression, major depression, single episode depression, recurrent depression, child abuse induced depression, and post partum depression in a mammal, comprising administering an effective amount of a compound according to Claim 2, or a pharmaceutically-acceptable salt thereof, and a pharmaceutically-acceptable carrier.

19. (new) A method for treating depression, comprising administering an effective amount of a compound according to Claim 2, or a pharmaceutically-acceptable salt thereof, and a pharmaceutically-acceptable carrier.

20. (new) A method for treating generalized anxiety disorder, comprising administering an effective amount of a compound according to Claim 2, or a pharmaceutically-acceptable salt thereof, and a pharmaceutically-acceptable carrier.

21. (new) A method for treating a disorder or condition selected from depression in cancer patients, depression in Parkinson's patients, postmyocardial infarction depression, subsyndromal symptomatic depression, depression in infertile women, pediatric depression, major depression, single episode depression, recurrent depression, child abuse induced depression, and post partum depression in a mammal, comprising administering an effective amount of a compound according to Claim 4, or a pharmaceutically-acceptable salt thereof, and a pharmaceutically-acceptable carrier.

22. (new) A method for treating depression, comprising administering an effective amount of a compound according to Claim 4, or a pharmaceutically-acceptable salt thereof, and a pharmaceutically-acceptable carrier.

23. (new) A method for treating generalized anxiety disorder, comprising administering an effective amount of a compound according to Claim 4, or a pharmaceutically-acceptable salt thereof, and a pharmaceutically-acceptable carrier.

24. (new) A compound according to Claim 1, wherein said compound is selected from:

1-N-Methyl-4-(3,4-dichlorophenyl)-4-(3-(3-cyanonaphth-1-yl)-(3-oxo-2-N-methyl-2-azaprop-1-yl))piperidine;

1-N-Methyl-4-(3,4-dichlorophenyl)-4-(3-(3-cyano-2-methoxynaphth-1-yl)-(3-oxo-2-N-methyl-2-azaprop-1-yl))piperidine;

4-(3,4-Dichlorophenyl)-4-(3-(3-cyano-2-methoxynaphth-1-yl)-3-oxo-2-azaprop-1-yl))piperidine;

1-N-Methyl-4-(3,4-dichlorophenyl)-4-(3-(3-cyano-2-methoxynaphth-1-yl)-3-oxo-2-azaprop-1-yl)piperidine;

4-(4-Chlorophenyl)-4-(3-(3-cyano-2-methoxynaphth-1-yl)-3-oxo-2-azaprop-1-yl)piperidine;

1-N-Methyl-4-(4-chlorophenyl)-4-(3-(3-cyano-2-methoxynaphth-1-yl)-3-oxo-2-azaprop-1-yl)piperidine;

1-N-(2-Methoxyethyl)-4-(4-chlorophenyl)-4-(3-(3-cyano-2-methoxynaphth-1-yl)-3-oxo-2-azaprop-1-yl)piperidine;

4-(3,4-Dichlorophenyl)-4-(3-(3-cyano-2,4-dimethoxynaphth-1-yl)-3-oxo-2-aza-prop-1-yl)piperidine;

4-(3,4-Dichlorophenyl)-4-(3-(3-cyano-2-ethylnaphth-1-yl)-3-oxo-2-azaprop-1-yl)piperidine;

1-N-Methyl-4-(3,4-dichlorophenyl)-4-(3-(3-cyano-2-ethylnaphth-1-yl)-3-oxo-2-azaprop-1-yl)piperidine;

1-N-Methyl-4-(4-fluorophenyl)-4-(3-(3-cyanonaphth-1-yl)-(3-oxo-2-azaprop-1-yl))piperidine;

1-N-Methyl-4-(4-fluorophenyl)-4-(3-(3-cyano-2-methoxynaphth-1-yl)-(3-oxo-2-azaprop-1-yl))piperidine;

1-N-Methyl-4-(4-fluorophenyl)-4-(3-(3-cyano-2-ethylnaphth-1-yl)-(3-oxo-2-azaprop-1-yl))piperidine;

1-N-Methyl-4-(4-fluorophenyl)-4-(3-(3-cyanonaphth-1-yl)-(3-oxo-2-N-methyl-2-azaprop-1-yl))piperidine;

3-cyano-N-((4-(3,4-difluorophenyl)-1-methylpiperidin-4-yl)methyl)-1-naphthamide;

3-cyano-N-((4-(3,4-difluorophenyl)-1-methylpiperidin-4-yl)methyl)-2-methoxy-1-naphthamide;

3-cyano-N-((4-(3,4-difluorophenyl)-1-methylpiperidin-4-yl)methyl)-2-ethyl-1-naphthamide;

3-cyano-N-((4-(3,4-difluorophenyl)-1-methylpiperidin-4-yl)methyl)-N-methyl-1-naphthamide;

3-cyano-N-((4-(4-methoxyphenyl)-1-methylpiperidin-4-yl)methyl)-1-naphthamide;

3-cyano-2-methoxy-N-((4-(4-methoxyphenyl)-1-methylpiperidin-4-yl)methyl)-1-naphthamide;

3-cyano-2-ethyl-N-((4-(4-methoxyphenyl)-1-methylpiperidin-4-yl)methyl)-1-naphthamide;

3-cyano-N-((4-(4-methoxyphenyl)-1-methylpiperidin-4-yl)methyl)-N-methyl-1-naphthamide;

3-cyano-N-((4-(3,4-dimethoxyphenyl)-1-methylpiperidin-4-yl)methyl)-1-naphthamide;

3-cyano-N-((4-(3,4-dimethoxyphenyl)-1-methylpiperidin-4-yl)methyl)-2-methoxy-1-naphthamide;

3-cyano-N-((4-(3,4-dimethoxyphenyl)-1-methylpiperidin-4-yl)methyl)-2-ethyl-1-naphthamide;

3-cyano-N-((4-(3,4-dimethoxyphenyl)-1-methylpiperidin-4-yl)methyl)-N-methyl-1-naphthamide;

3-cyano-N-((4-(4-(difluoromethoxy)phenyl)-1-methylpiperidin-4-yl)methyl)-1-naphthamide;

3-cyano-N-((4-(4-(difluoromethoxy)phenyl)-1-methylpiperidin-4-yl)methyl)-2-methoxy-1-naphthamide;

3-cyano-N-((4-(4-(difluoromethoxy)phenyl)-1-methylpiperidin-4-yl)methyl)-2-ethyl-1-naphthamide;

3-cyano-N-((4-(4-(difluoromethoxy)phenyl)-1-methylpiperidin-4-yl)methyl)-N-methyl-1-naphthamide;

3-cyano-N-((1-methyl-4-(4-(trifluoromethyl)phenyl)piperidin-4-yl)methyl)-1-naphthamide;

3-cyano-2-methoxy-N-((1-methyl-4-(4-(trifluoromethyl)phenyl)piperidin-4-yl)methyl)-1-naphthamide;

3-cyano-2-ethyl-N-((1-methyl-4-(4-(trifluoromethyl)phenyl)piperidin-4-yl)methyl)-1-naphthamide;

3-cyano-2,4-dimethoxy-N-((1-methyl-4-(4-(trifluoromethyl)phenyl)piperidin-4-yl)methyl)-1-naphthamide;

4-(4-Fluorophenyl)-4-(3-(3-cyanonaphth-1-yl)-3-oxo-2-azaprop-1-yl)piperidine;

4-(4-Fluorophenyl)-4-(3-(3-cyanonaphth-1-yl)-(3-oxo-2-N-methyl-2-azaprop-1-yl))piperidine;

4-(4-Fluorophenyl)-4-(3-(3-cyano-2-methoxynaphth-1-yl)-(3-oxo-2-azaprop-1-yl))piperidine;

4-(4-Fluorophenyl)-4-(3-(3-cyano-2-ethylnaphth-1-yl)-(3-oxo-2-azaprop-1-yl))piperidine;

4-(4-Fluorophenyl)-4-(3-(3-cyano-2,4-dimethoxynaphth-1-yl)-(3-oxo-2-azaprop-1-yl))piperidine;

1-N-Methyl-4-(4-fluorophenyl)-4-(3-(3-cyano-2,4-dimethoxynaphth-1-yl)-(3-oxo-2-azaprop-1-yl))piperidine;

1-N-Methyl-4-(4-fluorophenyl)-4-(3-(4-fluoronaphth-1-yl)-(3-oxo-2-azaprop-1-yl))piperidine;

1-N-Methyl-4-(4-fluorophenyl)-4-(3-(4-fluoronaphth-1-yl)-(3-oxo-2-N-methyl-2-azaprop-1-yl))piperidine;

1-N-Methyl-4-(3,4-difluorophenyl)-4-(3-(3-cyano-2,4-dimethoxynaphth-1-yl)-(3-oxo-2-azaprop-1-yl))piperidine;

1-N-Ethyl-4-(4-fluorophenyl)-4-(3-(3-cyanonaphth-1-yl)-3-oxo-2-azaprop-1-yl)piperidine;

1-N-Ethyl-4-(4-fluorophenyl)-4-(3-(3-cyano-2-methoxynaphth-1-yl)-3-oxo-2-azaprop-1-yl)piperidine;

1-N-Ethyl-4-(4-fluorophenyl)-4-(3-(3-cyanonaphth-1-yl)-3-oxo-2-N-methyl-2-azaprop-1-yl)piperidine;

1-N-Ethyl-4-(4-fluorophenyl)-4-(3-(3-cyano-2-ethylnaphth-1-yl)-3-oxo-2-azaprop-1-yl)piperidine;

1-N-Methyl-4-(4-fluorophenyl)-4-(3-(3-cyano-2,4-dimethoxynaphth-1-yl)-(3-oxo-2-azaprop-1-yl))piperidine;

1-N-Ethyl-4-(3,4-dichlorophenyl)-4-(3-(3-cyano-2-methoxynaphth-1-yl)-3-oxo-2-azaprop-1-yl)piperidine;

1-N-Ethyl-4-(3,4-dichlorophenyl)-4-(3-(3-cyanonaphth-1-yl)-3-oxo-2-azaprop-1-yl)piperidine;

1-N-Methyl-4-(3,4-dichlorophenyl)-4-(3-(3-cyanonaphth-1-yl)-3-oxo-2-azapro-1-yl)piperidine;

1-N-Methyl-4-(3-fluorophenyl)-4-(3-(3-cyanonaphth-1-yl)-3-oxo-2-azaprop-1-yl)piperidine;

1-N-Methyl-4-(3-fluorophenyl)-4-(3-(3-cyano-2-methoxynaphth-1-yl)-3-oxo-2-azaprop-1-yl)piperidine;

1-N-Methyl-4-(3-fluorophenyl)-4-(3-(3-cyano-2-ethylnaphth-1-yl)-3-oxo-2-azaprop-1-yl)piperidine;

1-N-Methyl-4-(3-fluorophenyl)-4-(3-(3-cyano-2,4-dimethoxynaphth-1-yl)-3-oxo-2-azaprop-1-yl)piperidine;

1-N-Methyl-4-phenyl-4-(3-(3-cyanonaphth-1-yl)-3-oxo-2-azaprop-1-yl)piperidine;

1-N-Methyl-4-phenyl-4-(3-(3-cyano-2-methoxynaphth-1-yl)-3-oxo-2-azaprop-1-yl)piperidine;

1-N-Methyl-4-phenyl-4-(3-(3-cyano-2-ethylnaphth-1-yl)-3-oxo-2-azaprop-1-yl)piperidine;

1-N-Methyl-4-phenyl-4-(3-(3-cyano-2,4-dimethoxynaphth-1-yl)-3-oxo-2-azaprop-1-yl)piperidine;

1-N-Methyl-4-phenyl-4-(3-(3-cyanonaphth-1-yl)-(3-oxo-2-N-methyl-2-azaprop-1-yl))piperidine;

1-N-Methyl-4-(4-fluorophenyl)-4-(3-(3-methoxy-4-methylnaphth-1-yl)-3-oxo-2-azaprop-1-yl)piperidine;

1-N-Methyl-4-(4-fluorophenyl)-4-(3-(4-chloro-3-methoxynaphth-1-yl)-3-oxo-2-azaprop-1-yl)piperidine;

1-N-Methyl-4-(4-fluorophenyl)-4-(3-(3-cyano-4-methylnaphth-1-yl)-3-oxo-2-azaprop-1-yl)piperidine;

1-N-Methyl-4-(4-fluorophenyl)-4-(3-(3-cyano-4-methylnaphth-1-yl)-(3-oxo-2-N-methyl-2-azaprop-1-yl))piperidine;

1-N-Methyl-4-(4-fluorophenyl)-4-(3-(4-bromonaphth-1-yl)-3-oxo-2-azaprop-1-yl)piperidine;

1-N-Methyl-4-(4-fluorophenyl)-4-(3-(4-bromonaphth-1-yl)-(3-oxo-2-N-methyl-2-azaprop-1-yl))piperidine;

3-cyano-N-((1-methyl-4-(3-fluorophenyl)piperidin-4-yl)methyl)-1-naphthamide;
3-cyano-2-methoxy-N-((1-methyl-4-(3-fluorophenyl)piperidin-4-yl)methyl)-1-naphthamide;
3-cyano-2-ethyl-N-((1-methyl-4-(3-fluorophenyl)piperidin-4-yl)methyl)-1-naphthamide;
3-cyano-2,4-dimethoxy-N-((1-methyl-4-(3-fluorophenyl)piperidin-4-yl)methyl)-1-naphthamide;
3-cyano-N-((1-methyl-4-phenylpiperidin-4-yl)methyl)-1-naphthamide;
3-cyano-2-methoxy-N-((1-methyl-4-phenylpiperidin-4-yl)methyl)-1-naphthamide;
3-cyano-2-ethyl-N-((1-methyl-4-phenylpiperidin-4-yl)methyl)-1-naphthamide;
3-cyano-2,4-dimethoxy-N-((1-methyl-4-phenylpiperidin-4-yl)methyl)-1-naphthamide;
and
3-cyano-N-methyl-N-((1-methyl-4-phenylpiperidin-4-yl)methyl)-1-naphthamide;
or pharmaceutically acceptable salt thereof.

25. (new) A compound selected from:

3-cyano-N-((4-(3,4-methylenedioxyphenyl)-1-methylpiperidin-4-yl)methyl)-1-naphthamide;
N-((4-(benzo[d][1,3]dioxol-5-yl)-1-methylpiperidin-4-yl)methyl)-3-cyano-2-methoxy-1-naphthamide;
N-((4-(benzo[d][1,3]dioxol-5-yl)-1-methylpiperidin-4-yl)methyl)-3-cyano-2-ethyl-1-naphthamide; and
N-((4-(benzo[d][1,3]dioxol-5-yl)-1-methylpiperidin-4-yl)methyl)-3-cyano-N-methyl-1-naphthamide;
or pharmaceutically acceptable salt thereof.

26. (new) A method for treating a disorder or condition selected from depression in cancer patients, depression in Parkinson's patients, postmyocardial infarction depression, subsyndromal symptomatic depression, depression in infertile women, pediatric depression, major depression, single episode depression, recurrent depression, child abuse induced depression, and post partum depression in a mammal, comprising administering an effective amount of a compound

according to Claim 25, or a pharmaceutically-acceptable salt thereof, and a pharmaceutically-acceptable carrier.

27. (new) A method for treating depression, comprising administering an effective amount of a compound according to Claim 25, or a pharmaceutically-acceptable salt, thereof, and a pharmaceutically-acceptable carrier.

28. (new) A method for treating generalized anxiety disorder, comprising administering an effective amount of a compound according to Claim 25, or a pharmaceutically-acceptable salt, thereof, and a pharmaceutically-acceptable carrier.